NATCO PHARMA LTD. - 524816 - Closure of Trading Window
TRADING WINDOW for dealing in the securities of the Company by the Employee(s) / Director(s) and their immediate relatives will be closed from 9th June, 2020 to 19th June, 2020 (both days inclusive). Trading window will be opened on 20th June, 2020. NATCO PHARMA LTD. - 524816 - Board to consider FY20 results & Fourth Interim Dividend on June 17, 2020
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on June 17, 2020, inter alia, to consider the following items of businesses and related matters:1. Approval of the Audited Financial Results for the quarter and year ended March 31, 2020.2. Consideration of fourth (4th) interim dividend, if any, for the financial year 2019-20.3. Convening of the thirty-seventh (37th) Annual General Meeting of the shareholders of the Company.Further note that pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, TRADING WINDOW for dealing in the securities of the Company by the Employee(s) / Director(s) and their immediate relatives will be closed from June 09, 2020 to June 19, 2020 (both days inclusive). Trading window will be opened on June 20, 2020. NATCO PHARMA LTD. - 524816 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year 2019-20 NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended 31St March, 2020
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/06/2020 ,inter alia, to consider and approve Audited Financial Results for the Quarter and year ended 31st March, 2020 NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO supports Columbia University's clinical trial of chloroquine phosphate to prevent symptomatic Covid-19 infections NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO's VIZAG FORMULATION FACILITY RECEIVES EIR Natco Pharma donates chloroquine for global study
Natco Pharma Limited has donated chloroquine phosphate tablets through its marketing partner in the US, Rising Pharmaceuticals, to support a global c NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO's Chloroquine for International Study to prevent SARS-CoV-2 infection In Frontline Healthcare Workers
Natco Pharma gains on US FDA approval; share up 27% in a month
The share price up 27 percent in last 1-month. NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO's VIZAG FORMULATION FACILITY RECEIVES USFDA APPROVAL